Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
Public ClinicalTrials.gov record NCT05926024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life and function, 3 years or more after the treatment, in cancer-free subjects. There will be 2 groups. Cohort A: Women who participated in previous studies namely NCT02167932, NCT02328313, and NCT03761706, will be re-contacted and consent for this study activities. Cohort B: Women with breast cancer, who did not receive chemotherapy, will be consented to be included in the study, and their electronic medical data will be used. Furthermore, the long-term effects of treatment and a biomarker of aging cyclin-dependent kinase inhibitor 2A (CDKN2A,p16INK4a) and relation will be assessed.
Study identification
- NCT ID
- NCT05926024
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 253 participants
Conditions and interventions
Conditions
Interventions
- Exercise Recall Patient Reported Outcomes Behavioral
- Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes Behavioral
- Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes Behavioral
- Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes Behavioral
- Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a) Behavioral
- Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Behavioral
- Patient Reported Outcomes PROMIS Behavioral
- Patient Reported Outcomes FACT-Endocrine Symptoms Behavioral
- Patient Reported Outcomes Penn Arthralgia Aging Survey Behavioral
- Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE) Behavioral
- p16 tumor suppressor gene Diagnostic Test
Behavioral · Diagnostic Test
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 5, 2023
- Primary completion
- Jan 30, 2028
- Completion
- Jan 30, 2028
- Last update posted
- Mar 10, 2026
2023 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05926024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05926024 live on ClinicalTrials.gov.